Phase III randomized clinical study in metastatic pancreatic cancer completed enrollment sNDA submitted to U.S. FDA in non-small cell lung cancer, PDUFA date Oct. 12, 2012 CALGB 40502 advances understanding of optimal dosing and scheduling of nab-paclitaxel in metastatic breast cancer BOUDRY, Switzerland–(BUSINESS WIRE)–Jun. 6, 2012– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: […]
SUMMIT, N.J.–(BUSINESS WIRE)–Mar. 8, 2012– Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila’s discovery program. The transaction provides Celgene with a highly-selective Bruton’s tyrosine […]
SUMMIT, N.J.–(BUSINESS WIRE)–Feb. 27, 2012– Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company’s Web site at http://www.celgene.com. Celgene management will provide an overview of the Company. •Tuesday, March 6, 2012 Celgene will present at the […]
Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases Avilomics™ Platform enhances drug discovery capabilities SUMMIT, N.J. and BEDFORD, Mass.–(BUSINESS WIRE)–Jan. 26, 2012– Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement […]
Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government policy. He served as Director General of the Association of the British Pharmaceutical Industry (ABPI), and as a board member for the European and International […]
SUMMIT, N.J.–(BUSINESS WIRE)–Dec. 22, 2011– Celgene Corporation (NASDAQ: CELG) today announced the appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access, effective January 30th. Mr. Bagger will be responsible for all government and public affairs, strategic market access, communications and patient advocacy initiatives and will report to Robert J. Hugin, […]
TRENTON, N.J.–(BUSINESS WIRE)–BioNJ, New Jersey’s trade association for the biotechnology community, announced today that the fifth annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership has been awarded to Paul G. Thomas, Founder and CEO of Roka Bioscience. Named for Sol J. Barer, Ph.D., a Senior Advisor and former Chairman and CEO of […]
Patients achieving complete response had a median overall survival of 27 months BOUDRY, Switzerland, Dec 12, 2011 (BUSINESS WIRE) –Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients […]
Study Reported Overall Response Rate of 38%, and REVLIMID® (Lenalidomide) Was Well Tolerated BOUDRY, Switzerland–(BUSINESS WIRE)–Dec. 11, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID® (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia […]
REVLIMID(R) Granted Swissmedic Approval for Treatment of Rare Blood Cancer BOUDRY, Switzerland–(BUSINESS WIRE)–Nov. 21, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG) today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes […]
Daily updates about the region's most tech savvy companies
